Stage (next event)
Catalyst Info & Data Links
TITLE: Allogenic iNTKs for Cancer treatment Phase 1 Commencement
WHAT IS THE NEXT CATALYST EVENT?
Phase 1 trial commencement
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Mechanism of Action
MECHANISM OF ACTION
Invariant natural killer T cells (iNKT cells) are a unique cell type that combines features of two critical arms of the immune system, T cells (adaptive immunity) and NK cells (innate immunity), making them invaluable in combating diseases like COVID-19 and cancer. Data from preclinical models that bear similarities to SARS-COV-2 suggest that iNKT cell therapy has the potential to eliminate the COVID-19 virus, dampen harmful inflammation, and promote protection from reinfection.
As for cancer, data from preclinical models show that AgenTus iNKTs can penetrate tissues, giving them a critical advantage in targeting solid tumors not currently served by approved cell therapies. These data also showed that the combination of checkpoint antibodies and iNKT cell triggering therapy shows curative potential in cancer models that are refractory to available therapies.
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post